Maki Kobayashi

6PUBLICATIONS
87CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 17, 2026
Changes and clinical impact of HER3 and ERBB3 expression in primary and recurrent ovarian cancer.

|Dec 16, 2024
The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer.

Shigehiro Koganemaru, Shohei Koyama, Fumitaka Suto

|Aug 20, 2024
Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer.

Naoko Iida, Mitsuho Imai, Wataru Okamoto

|Jun 19, 2024
The Comprehensive Characterization of B7-H3 Expression in the Tumor Microenvironment of Lung Squamous Cell Carcinoma: A Retrospective Study.

Ayaka Asakawa, Ryoto Yoshimoto, Maki Kobayashi

|Jul 24, 2023
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.

Fernanda Mosele, Elise Deluche, Amelie Lusque

|Dec 18, 2021
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.

Kimio Yonesaka, Junko Tanizaki, Osamu Maenishi

Pageof 1

Frequent Collaborators

2 joint publications

Satoshi Fujii

1 joint publications

Kimio Yonesaka

1 joint publications

Junko Tanizaki

1 joint publications

Koji Haratani